Boule Diagnostics AB will publish their interim report for the period January – September 2017 at 08:45, Wednesday, 8 November. In connection to the release, Boule will hold a webinar including a presentation and conference call for media and investors.
CEO Fredrik Dahlborg, and CFO Christina Rubenhag, presents and comment the interim report. After the presentation there will be time for audience questions. The presentation will be held in English.
Time: 14.00 CET, Wednesday, 8 November 2017
||+46(0)8 5352 6408
||+44(0)20 3478 5300
||+1718 354 1357
Confirm your connection and participation to the conference call, by dialing in and register a few minutes before the presentation begins.
The link to the live-feed will be published at https://edge.media-server.com/m6/p/e7tdr84r
The interim report will be accessible at http://www.boule.com when published.
Please feel free to attend this event!
For further information, please contact:
Fredrik Dalborg, CEO and President, Boule Diagnostics AB, phone +46 705-58 51 05
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 705-46 72 22
About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a rapidly growing global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden and the USA. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com